logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover

MNKD
MannKind Corporation
4.05
2 x 3.05
2 x 5.29
bid
ask
-
0.21
4.93%
2 @ 06:19 AM
4.00 -0.05 (1.23%)
Ytd-28.57%
1y13.13%
4.05
day range
4.30
2.23
52 week range
6.51
Open4.29Prev Close4.26Low4.05High4.30Mkt Cap1.25B
Vol2.72MAvg Vol5.47MEPS-0.07P/EN/AForward P/E21.04
Beta1.11Short Ratio5.91Inst. Own59.28%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg3.42200-d Avg4.471yr Est7.59

MNKD News

benzinga.com
MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new op

benzinga.com
Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Eff

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 a

Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends
benzinga.com
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War

Cramer put Photronics in the penalty box due to poor results. He praised Woodward and warned against

benzinga.com
MannKind Announces Key Clinical Execution Milestones In The Development Of Nintedanib DPI For Idiopa

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, pa